FREE TRIAL Receive 30 days of no-obligation access. SIGN UP

Home

Top Story

Senate Finance Draft Aims To Change Hospital, GPO Drug Procurement

The Senate Finance Committee released a draft bill that would create a new program within Medicare aimed at incentivizing hospitals, group purchasing organizations (GPOs) and other drug supply chain stakeholders to help create stable pricing for generic drug manufacturers by rewarding quality, reliability and long-term sustainable contracts.

Latest News

Admin Offers Subsidized ACA Plans To DACA Recipients, Punts On Medicaid

Democratic lawmakers, patient advocates and other stakeholders are cheering the Biden administration for extending subsidized Affordable Care Act coverage to DACA-recipients starting Nov. 1 in a long-awaited final rule out Friday (May 3).

Public Citizen Hits Eli Lilly For Not Disclosing Lobbying Expenses Ahead Of Shareholder Vote

As a handful of key Senate Democrats and consumer advocates engage in a broader effort to get companies to disclose lobbying expenses, Public Citizen on Friday (May 3) blasted drug maker Eli Lilly for not making all its expenditures public in the run-up to its annual meeting next week where shareholders are slated to hold a vote demanding transparency.

Cassidy Calls For More Bird Flu Transparency From FDA, Administration

The ranking Republican on the Senate health committee, Sen. Bill Cassidy (LA), is asking the Biden administration to provide more transparency on its gathering of scientific evidence surrounding the current outbreak of avian influenza, including information about the testing FDA is doing to measure the safety of the milk supply.

CMS Extends Enforcement Discretion For No Surprises Act QPA Calculations

Health insurers can use an invalidated methodology to calculate the qualifying payment amounts (QPAs), or median in-network rates, that are integral to the No Surprises Act’s patient cost-sharing requirements -- and its independent dispute resolution (IDR) process -- for an additional six months, CMS announced this week.

GOP Skeptical Of Research Collaboration With China, NIH Oversight

Republicans raised concerns about any research collaboration between the United States and China at a House hearing this week, arguing work with scientists from China is inherently problematic, but a health researcher defended the work as necessary to guard against future pandemics.

New CDER Center Could Boost Decentralized, Community-Based Trials

Experts say the new center set up by FDA drug officials to boost clinical trial innovation has the potential to increase diverse enrollment in trials, and they hope the new initiative will end up encouraging decentralized trials, including greater use of wearable apps, and community-based approaches to recruitment.